ACTU insider transaction filings
ACTUATE THERAPEUTICS, INC. — 41 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-14. Screen ACTU transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 3.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| SCHMITT DANIEL M — President, CEO and Director, Director | 1 | — | — | 3 |
Recent Form 4 filings — ACTUATE THERAPEUTICS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | SCHMITT DANIEL M — President, CEO and Director, Director | Option exercise (M): 272,056 @ $0 · Tax withholding (F): 120,521 @ $1.01 · Option exercise (M): 272,056 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Zabrowski Dan — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Sawhney Roger — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Keyes Jason A — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Huber Martin H. Jr. — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Fletcher Aaron G.L. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | RONNEBERG AMY L — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | THOMSON TODD S — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Mazar Andrew Paul — Chief Operating Officer | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | SCHMITT DANIEL M — President, CEO and Director, Director | Grant/award (A): 237,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | LYTLE PAUL J — Chief Financial Officer | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | SCHMITT DANIEL M — President, CEO and Director, Director | Option exercise (M): 272,055 @ $0 · Tax withholding (F): 121,874 @ $4.33 · Option exercise (M): 272,055 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | THOMSON TODD S — Director, 10% owner Kairos Venture Partners II, L.P. — Director, 10% owner | Sale (S): 280,000 @ $5.80 | EDGAR |
| 2025-06-30 | 4 | Bios Equity COF, LP — Director, 10% owner Bios Clinical Opportunity Fund, LP — Director, 10% owner Bios 2024 Co-Invest, LP — Director, 10% owner BP Directors, LP — Director, 10% owner | Purchase (P): 71,428 @ $7 · Purchase (P): 71,428 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Kreis Leslie W. — Director, 10% owner Cavu Advisors, LLC — Director, 10% owner Cavu Management, LP — Director, 10% owner BIOS Fund I, LP — Director, 10% owner BIOS Fund I QP, LP — Director, 10% owner Bios Equity Partners, LP — Director, 10% owner BIOS Fund II, LP — Director, 10% owner BIOS Fund II NT, LP — Director, 10% owner BIOS Fund II QP, LP — Director, 10% owner Bios Equity Partners II, LP — Director, 10% owner | Purchase (P): 71,428 @ $7 · Purchase (P): 71,428 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Fletcher Aaron G.L. — Director, 10% owner BIOS Capital Management, LP — Director, 10% owner BIOS Advisors GP, LLC — Director, 10% owner BIOS Fund III, LP — Director, 10% owner BIOS Fund III QP, LP — Director, 10% owner BIOS Fund III NT, LP — Director, 10% owner BIOS Actuate Co-Invest I, LP — Director, 10% owner BIOS Actuate Co-Invest II, LP — Director, 10% owner Bios Actuate Co-Invest III, LP — Director, 10% owner BIOS Equity Partners III, LP — Director, 10% owner | Purchase (P): 71,428 @ $7 · Purchase (P): 71,428 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Sawhney Roger — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Keyes Jason A — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Zabrowski Dan — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Fletcher Aaron G.L. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | RONNEBERG AMY L — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | THOMSON TODD S — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Mazar Andrew Paul — Chief Operating Officer | Grant/award (A): 51,046 (derivative) @ $0 · Grant/award (A): 110,346 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | SCHMITT DANIEL M — President, CEO and Director, Director | Grant/award (A): 66,503 (derivative) @ $0 · Grant/award (A): 204,285 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | LYTLE PAUL J — Chief Financial Officer | Grant/award (A): 49,394 (derivative) @ $0 · Grant/award (A): 41,899 (derivative) @ $0 | EDGAR |
| 2024-08-20 | 4/A | Bios Equity COF, LP — Director, 10% owner Bios Clinical Opportunity Fund, LP — Director, 10% owner BP Directors, LP — Director, 10% owner | Sale (S): 5,314 @ $8 · Sale (S): 17,361 @ $8 · Sale (S): 2,324 @ $8 | EDGAR |
| 2024-08-20 | 4/A | Fletcher Aaron G.L. — Director, 10% owner BIOS Capital Management, LP — Director, 10% owner BIOS Advisors GP, LLC — Director, 10% owner BIOS Fund III, LP — Director, 10% owner BIOS Fund III QP, LP — Director, 10% owner BIOS Fund III NT, LP — Director, 10% owner BIOS Actuate Co-Invest I, LP — Director, 10% owner BIOS Actuate Co-Invest II, LP — Director, 10% owner Bios Actuate Co-Invest III, LP — Director, 10% owner BIOS Equity Partners III, LP — Director, 10% owner | Sale (S): 5,314 @ $8 · Sale (S): 17,361 @ $8 · Sale (S): 2,324 @ $8 | EDGAR |
| 2024-08-20 | 4/A | Kreis Leslie W. — 10% owner Cavu Advisors, LLC — Director, 10% owner Cavu Management, LP — Director, 10% owner BIOS Fund I, LP — Director, 10% owner BIOS Fund I QP, LP — Director, 10% owner Bios Equity Partners, LP — Director, 10% owner BIOS Fund II, LP — Director, 10% owner BIOS Fund II NT, LP — Director, 10% owner BIOS Fund II QP, LP — Director, 10% owner Bios Equity Partners II, LP — Director, 10% owner | Sale (S): 5,314 @ $8 · Sale (S): 17,361 @ $8 · Sale (S): 2,324 @ $8 | EDGAR |
| 2024-08-16 | 4 | THOMSON TODD S — Director Kairos SPV Fund LLC — Director Kairos Venture Opportunities I, L.P. — Director Kairos Venture Partners II, L.P. — Director Kairos-Actuate SPV, L.P. — Director | Conversion (C): 1,058,318 · Conversion (C): 726,163 · Conversion (C): 69,445 · Conversion (C): 146,870 · Conversion (C): 138,889 · Conversion (C): 230,597 · +16 more | EDGAR |
| 2024-08-14 | 4 | Sawhney Roger — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Bios Equity COF, LP — Director, 10% owner Bios Clinical Opportunity Fund, LP — Director, 10% owner BP Directors, LP — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2024-08-14 | 4 | Bios Equity COF, LP — Director, 10% owner Bios Clinical Opportunity Fund, LP — Director, 10% owner BP Directors, LP — Director, 10% owner | Conversion (C): 884,427 · Purchase (P): 375,000 @ $8 · Purchase (P): 125,000 @ $8 · Conversion (C): 525,797 · Conversion (C): 307,538 · Conversion (C): 141,457 · +50 more | EDGAR |
| 2024-08-14 | 4 | Fletcher Aaron G.L. — Director, 10% owner BIOS Capital Management, LP — Director, 10% owner BIOS Advisors GP, LLC — Director, 10% owner BIOS Fund III, LP — Director, 10% owner BIOS Fund III QP, LP — Director, 10% owner BIOS Fund III NT, LP — Director, 10% owner BIOS Actuate Co-Invest I, LP — Director, 10% owner BIOS Actuate Co-Invest II, LP — Director, 10% owner Bios Actuate Co-Invest III, LP — Director, 10% owner BIOS Equity Partners III, LP — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2024-08-14 | 4 | Fletcher Aaron G.L. — Director, 10% owner BIOS Capital Management, LP — Director, 10% owner BIOS Advisors GP, LLC — Director, 10% owner BIOS Fund III, LP — Director, 10% owner BIOS Fund III QP, LP — Director, 10% owner BIOS Fund III NT, LP — Director, 10% owner BIOS Actuate Co-Invest I, LP — Director, 10% owner BIOS Actuate Co-Invest II, LP — Director, 10% owner Bios Actuate Co-Invest III, LP — Director, 10% owner BIOS Equity Partners III, LP — Director, 10% owner | Conversion (C): 884,427 · Purchase (P): 375,000 @ $8 · Purchase (P): 125,000 @ $8 · Conversion (C): 525,797 · Conversion (C): 307,538 · Conversion (C): 141,457 · +50 more | EDGAR |
| 2024-08-14 | 4 | Kreis Leslie W. — 10% owner Cavu Advisors, LLC — Director, 10% owner Cavu Management, LP — Director, 10% owner BIOS Fund I, LP — Director, 10% owner BIOS Fund I QP, LP — Director, 10% owner Bios Equity Partners, LP — Director, 10% owner BIOS Fund II, LP — Director, 10% owner BIOS Fund II NT, LP — Director, 10% owner BIOS Fund II QP, LP — Director, 10% owner Bios Equity Partners II, LP — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2024-08-14 | 4 | Kreis Leslie W. — 10% owner Cavu Advisors, LLC — Director, 10% owner Cavu Management, LP — Director, 10% owner BIOS Fund I, LP — Director, 10% owner BIOS Fund I QP, LP — Director, 10% owner Bios Equity Partners, LP — Director, 10% owner BIOS Fund II, LP — Director, 10% owner BIOS Fund II NT, LP — Director, 10% owner BIOS Fund II QP, LP — Director, 10% owner Bios Equity Partners II, LP — Director, 10% owner | Conversion (C): 884,427 · Purchase (P): 375,000 @ $8 · Purchase (P): 125,000 @ $8 · Conversion (C): 525,797 · Conversion (C): 307,538 · Conversion (C): 141,457 · +50 more | EDGAR |
| 2024-08-14 | 4 | Zabrowski Dan — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Keyes Jason A — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | RONNEBERG AMY L — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | SCHMITT DANIEL M — President, CEO and Director, Director | Grant/award (A): 544,111 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | LYTLE PAUL J — Chief Financial Officer | Grant/award (A): 234,971 (derivative) @ $0 | EDGAR |
Recent 8-K events — ACTUATE THERAPEUTICS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-17 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-05-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-21 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-09-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-05 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ACTU returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →